ConductScience.org, home

Paper890691

Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents.

Von Hoff DD and 6 others. Cancer Treat Rep, 1977. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents. Papers, record 890691. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/890691

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Whatever happened to NSC--? An analysis of clinical results of discontinued anticancer agents.
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1977
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
0.95
iCite
Revised in PubMed
2004-11-17
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Von Hoff DDD D
2Rozencweig MM
3Soper WTW T
4Helman LJL J
5Penta JSJ S
6Davis HLH L
7Muggia FMF M

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Alkylating Agents
Drug Evaluation
Hormones
Humans
Neoplasms
Purine Nucleosides
Pyrimidine Nucleosides

Source PubMed

Download CSV of topics

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
36087287Peptidylarginine deiminase enzymes and citrullinated proteins in female reproductive physiology and associated diseases†.Biol Reprod2022https://conductscience.org/library/papers/36087287PubMed
27366142Recent developments on potential new applications of emetine as anti-cancer agent.EXCLI J2016https://conductscience.org/library/papers/27366142PubMed
24328139Total synthesis of the antitumor antibiotic (±)-streptonigrin: first- and second-generation routes for de novo pyridine formation using ring-closing metathesis.J Org Chem2013https://conductscience.org/library/papers/24328139PubMed
22867001Design, synthesis, and evaluation of pH-dependent hydrolyzable emetine analogues as treatment for prostate cancer.J Med Chem2012https://conductscience.org/library/papers/22867001PubMed
393427m-AMSA and PALA: two new agents in cancer chemotherapy.Cancer Chemother Pharmacol1979https://conductscience.org/library/papers/393427PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/890691

GET https://conductscience.org/api/papers/v1/890691/authors